◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › LABT

Lakewood-Amedex Biotherapeutics, Inc. (LABT) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

Lakewood-Amedex Biotherapeutics, Inc. (LABT) operates in the Biotechnology industry and is headquartered in University Park, United States with about 5 employees. Its market capitalization is roughly $3 million. In the fiscal year ended 2025-12-31, LABT reported $0M in revenue and ($4M) in net income.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.

Interactive charts & full statements →

LABT Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-31
Total Revenue$0M$0M$0M
Operating Income (EBIT)($4M)($4M)($9M)
Net Income($4M)($5M)($8M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LABT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($1M)($1M)($2M)($0M)($1M)
Net Income($1M)($1M)($2M)($0M)($1M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LABT Free Cash Flow History

LABT Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-31
Total Assets$0M$1M$7M
Total Liabilities$2M$1M$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LABT viewer.

Other Companies in Biotechnology

← LABAll stocksLAC →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.